Bank of Nova Scotia’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-32,015
Closed -$8.36M 1276
2022
Q1
$8.36M Buy
+32,015
New +$7.6M 0.01% 490

Other funds holding VRTX

Bank of Nova Scotia's VRTX Position: Q2 2026 in Review

Bank of Nova Scotia reduced its Vertex Pharmaceuticals (VRTX) stake by 22% in Q2 2026, selling an estimated $3.44M and leaving 27,607 shares worth $13.7M. The position accounts for 0.02% of the portfolio, ranked #425.

Bank of Nova Scotia first reported a position in VRTX in Q3 2013 and has held it in 52 quarters since. The position peaked at $121M in Q2 2020. 1,296 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Bank of Nova Scotia held 27,607 shares of Vertex Pharmaceuticals worth $13.7M as of Q2 2026.
  • Bank of Nova Scotia sold 7,754 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.44M.
  • Vertex Pharmaceuticals made up 0.02% of Bank of Nova Scotia's portfolio in Q2 2026, its #425 holding.
  • Bank of Nova Scotia first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 52 quarters since.
  • Bank of Nova Scotia's Vertex Pharmaceuticals position peaked at $121M in Q2 2020.
  • 1,296 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Bank of Nova Scotia's 13F filing for Q2 2026, filed 12 Aug 2026.